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Abstract
Background: Heart failure patients with stable angina, acute coronary syndromes and valvular heart disease may
benefit from revascularisation and/or valve surgery. However, the mortality rate is increased- 5-30%. Biventricular
pacing using temporary epicardial wires after surgery is a potential mechanism to improve cardiac function and
clinical endpoints.
Method/design: A multi-centred, prospective, randomised, single-blinded, intervention-control trial of temporary
biventricular pacing versus standard pacing. Patients with ischaemic cardiomyopathy, valvular heart disease or both,
an ejection fraction ≤ 35% and a conventional indication for cardiac surgery will be recruited from 2 cardiac
centres. Baseline investigations will include: an electrocardiogram to confirm sinus rhythm and measure QRS
duration; echocardiogram to evaluate left ventricular function and markers of mechanical dyssynchrony;
dobutamine echocardiogram for viability and blood tests for renal function and biomarkers of myocardial injury-
troponin T and brain naturetic peptide. Blood tests will be repeated at 18, 48 and 72 hours. The principal
exclusions will be subjects with permanent atrial arrhythmias, permanent pacemakers, infective endocarditis or end-
stage renal disease.
After surgery, temporary pacing wires will be attached to the postero-lateral wall of the left ventricle, the right
atrium and right ventricle and connected to a triple chamber temporary pacemaker. Subjects will be randomised
to receive either temporary biventricular pacing or standard pacing (atrial inhibited pacing or atrial-synchronous
right ventricular pacing) for 48 hours.
The primary endpoint will be the duration of level 3 care. In brief, this is the requirement for invasive ventilation,
multi-organ support or more than one inotrope/vasoconstrictor. Haemodynamic studies will be performed at
baseline, 6, 18 and 24 hours after surgery using a pulmonary arterial catheter. Measurements will be taken in the
following pacing modes: atrial inhibited; right ventricular only; atrial synchronous-right ventricular; atrial
synchronous-left ventricular and biventricular pacing. Optimisation of the atrioventricular and interventricular delay
will be performed in the biventricular pacing group at 18 hours. The effect of biventricular pacing on myocardial
injury, post operative arrhythmias and renal function will also be quantified.
Trial Registration: ClinicalTrials.gov: NCT01027299
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The prevalence of heart failure is increasing throughout
the industrialised world. Approximately 2-3% of the gen-
eral population are diagnosed with heart failure [1] and
the primary aetiology is coronary artery disease. A retro-
spective analysis of heart failure trials has identified at
least 62% of subjects have coronary disease [2]. The total
financial cost to the National Health Service is approxi-
mately £ 563 million per annum in 2006-7[3].
Modern medical therapy has substantial reduced both
morbidity and mortality after a myocardial infarction.
ACE inhibitors [4,5], beta blockers [6-8] and aldosterone
antagonists [9,10] modulate the renin-angiotensin-aldos-
terone axis and neurohormonal cascade which reduces
major adverse events. These medications arrest the cas-
cade of progressive ventricular remodelling and dilatation
observed in heart failure. Further ventricular remodelling
can be achieved with biventricular (BiV) pacing through
the reversal of electro-mechanical dyssynchrony. The
reduction in ventricular volumes correlates to a reduc-
tion in heart failure events, arrhythmias and death
[11,12].
Heart failure patients with stable angina and a significant
burden of coronary artery disease may benefit from surgi-
cal revascularisation. However, the risk of surgery is
increased and mortality rates range from 5-30% [13].
There is limited randomised control data on surgical
revascularisation in subjects with severe left ventricular
(LV) systolic dysfunction- ejection fraction ≤ 35%. The
landmark trials of surgical revascularisation in the 1970
excluded subjects with significant LV dysfunction [14,15].
The Coronary-Artery Bypass Surgery in Patients with
LV Dysfunction (STICH) trial was specifically designed to
address this issue and compared optimal medical therapy
to surgical revascularisation, in subjects with severe LV
systolic impairment [16]. The primary endpoint of all
cause mortality was not significant between the 2 groups
at 56 months follow-up (41% medical v 36% surgical; p =
0.12). However, the secondary endpoint of death or cardi-
ovascular hospitalisation was less likely in the surgical
group (68% v 58%; p < 0.001).
A sub-study of the STICH trial (n = 601) also investi-
gated the prognostic value of myocardial viability in
patients with severe LV systolic impairment [17]. Viability
was assessed using single-photon emission computer
tomography or dobutamine echo. After adjustment for
baseline variables there was no significant association
between viability and mortality (p = 0.21). Neither was
there a significant interaction between viability status and
treatment assignment with respect to mortality (p = 0.53).
However, previous meta-analysis of viability (n = 3088)
reported a 79.6% reduction in annual mortality with revas-
cularisation versus medical therapy when viable myocar-
dium was detected (16% v 3.2%, p < 0.0001) [18]. There
was no advantage of revascularisation in non-viable
myocardium.
The ESC guidelines on myocardial revascularisation
2010 [13] recommend surgical revascularisation in
chronic heart failure (ejection fraction ≤ 35%) in the fol-
lowing circumstances- Table 1:
In addition, heart failure patients with unstable coronary
syndromes and valvular heart disease are potential candi-
dates for cardiac surgery. In view of the increased pre-
operative risk of surgery, interest has focused on techni-
ques including temporary BiV pacing, to optimise cardiac
function and outcome in the post operative period.
BiV pacing can be performed after cardiac surgery via
temporary epicardial wires attached to the right atrium,
right and left ventricle. Through a mechanism of reversing
electro-mechanical dyssynchrony, BiV pacing can augment
stroke volume and cardiac output without increasing myo-
cardial oxygen demand. An acute haemodynamic response
has been observed in previous studies during implantation
of permanent BiV pacemakers - Table 2.
These studies were conducted on subjects after opti-
mising medical therapy including ACE inhibitors and
beta blockers. Temporary BiV pacing after cardiac sur-
gery has additional considerations. The haemodynamic
performance of this technique maybe affected in the
presence of inotropes and vasopressors, anaesthetic
agents, intra-aortic balloon counter-pulsation, positive
pressure ventilation and myocardial injury after circula-
tory arrest. In addition, ACE inhibitors are frequently
discontinued prior to surgery because of post operative
hypotension and renal dysfunction [19].
Previous trials of temporary BiV pacing after cardiac
surgery have produced mixed results- Table 3.
The largest trial in this series (Pokushalov et al [20])
enrolled subjects with baseline dyssynchrony. This
included a QRS duration > 120 msec or the echo cri-
teria for dyssynchrony used in the CARE-HF trial [21].
In addition, the effect of BiV pacing was not measured
Table 1 Indications for surgical revascularisation in heart
failure.
Indication Class Level
CABG is recommended for: I B
￿ Significant left main stenosis
￿ Left main equivalent
￿ Proximal LAD stenosis, with 2 or 3 vessel disease
LV aneurysmectomy during CABG is indicated in patients
with a large LV aneurysm.
IC
CABG should be considered in the presence of viable
myocardium irrespective of LV end-systolic volumes.
IIa B
CABG with ventricular reconstruction may be considered
in patients with scarred LAD territory.
IIb B
Revascularisation in the absence of myocardial viability is
not recommended.
III B
Russell et al. Trials 2012, 13:20
http://www.trialsjournal.com/content/13/1/20
Page 2 of 8in subjects with an intra-aortic balloon pump. There-
fore, additional studies to assess the clinical and haemo-
dynamic effects of BiV pacing in all subjects in sinus
rhythm with severe LV systolic impairment, ejection
fraction (EF) ≤ 35% irrespective of baseline dyssyn-
chrony are indicated. This includes haemodynamic stu-
dies of BiV pacing in subjects who require intra-aortic
balloon counter-pulsation and further evaluation of
atrioventricular (AV) and interventricular (VV)
optimisation.
Methods/Design
Hypothesis
￿ Post operative biventricular pacing may improve
acute haemodynamic function after surgery by rever-
sal of electro-mechanical dyssynchrony.
￿ Temporary BiV pacing may reduce the require-
ments for inotropic support, ventilation and renal
replacement therapy and hence the duration of level
3 care.
￿ Optimisation of BiV pacing intervals may provide
additional haemodynamic benefit compared to nom-
inal settings.
Study design
A multi-centred, prospective, randomised, single-blinded,
intervention-control trial of patients with severely
impaired LV systolic function (EF ≤ 35%) undergoing car-
diac surgery for revascularisation, valve surgery or both.
Inclusion and exclusion criteria are detailed in Table 4.
The trial was approved by the ‘Research and Develop-
ment’ departments, at the University Hospital of Wales,
Cardiff (09/CAD/4628-sponsor) and Morriston Hospital,
Swansea, UK (S10CardS961). The trial has been
approved by the Dyfred Powys Research Ethics Commit-
tee-09/WMW01/27. The trial will be conducted in
accordance with the ‘Declaration of Helsinki’ and all
subjects will provide written consent. This trial is regis-
tered with clinicaltrials.gov NCT01027299.
Table 2 Trials of acute haemodynamic response to biventricular pacing.
Investigator Study title Sample Result
Breithardt [26], 2003. Acute effects of CRT on MR in systolic heart failure. N = 24
EF ≤ 30%
LBBB
Reduction in MR and improvement in dP/
dT with BiV, p < 0.0001.
Leclerq [27], 1998. Acute haemodynamic effects of BiV in patients with end-
stage heart failure.
N=1 8
NYHA ≥ 3
QRS ≥ 120
Increase in cardiac index BiV pacing v AAI,
p < 0.001.
Aurrichio [28], 1999. Effect of pacing chamber and AV delay on acute systolic
function of paced patients with heart failure.
N=2 7
NYHA ≥ 3
LBBB
Improvement in LV dP/dT with BiV pacing
v DDD(RV) pacing, p < 0.01.
Kass [29], 1999. Improved LV mechanics from acute VDD pacing in patients
with DCM and conduction delay.
N=1 8
QRS ≥ 120
Improvement in LV dP/dT with BiV pacing
v AAI, p < 0.05.
Table 3 Acute BiV pacing studies after cardiac surgery.
Investigator Study title Sample Result
Pokushalov [20],
2010.
CABG with CRT in patients with ischaemic heart failure
and dyssynchrony.
N = 178
EF ≤ 35%
QRS > 120
Reduced mortality with CRT, p = 0.006, reduced
LOS and improved CI at 48 hours, p < 0.001.
Eberhardt [30],
2009.
BiV pacing after CABG in patients with reduced LV
function.
N=9 4
EF ≤ 40%
No significant difference between BiV and other
pacing modes on haemodynamics or LOS.
Hanke [24], 2009. BiV pacing after cardiopulmonary bypass in patients with
reduced LV function.
N=2 1
EF < 35%
QRS > 120
BiV superior to DDD(RV) pacing but not DDD(LV)
or AAI pacing.
Evonich [31],
2008.
Temporary BiV pacing in cardiac patients with severely
reduced LV function.
N=4 0
EF ≤ 30%
No significant change in LOS or haemodynamic
function with BiV.
Hamad [32],
2009.
Acute haemodynamic effect of CRT in patients with poor
LV function during surgery.
N=1 1
QRS > 130
EF ≤ 35%
Optimised (VV) BIV pacing improved
haemodynamics (p = 0.03) v RV pacing.
Muehlschlegel
[33], 2008.
Temporary BiV pacing after CABG in patients with
reduced ejection fraction.
N=1 0
EF < 50%
QRS > 120
Significant improvement in cardiac output with
BiV v DDD(RV or LV).
Dzemali [34],
2008.
Impact of different pacing modes on LV function
following CABG.
N=8 0
EF ≤ 35%
Patients with dilated LV (mean 65 v 52mm) more
likely to respond to BiV, p < 0.001.
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Patients will be invited to participate in the trial if they are
awaiting cardiac surgery. This includes elective patients
and in-house referrals scheduled for revascularisation,
valve surgery or both. Subjects with a recent history of an
acute coronary syndrome or episode of decompensated
heart failure (< 30 days) will be included. However,
unstable subjects with medically refractory angina and/or
pulmonary oedema requiring emergency surgery will be
excluded from the trial.
After enrolment an ECG will be performed to confirm
sinus rhythm and measure QRS duration and a transthor-
acic echocardiogram to measure ejection fraction using
the Simpson’s bi-plane method of discs. A detailed echo
study will be performed (GE, Vivid 7, Horten, Norway), to
evaluate LV systolic and diastolic function, valve function
and cardiac dyssynchrony- Table 5. Subjects with EF >
35% will exit the trial.
Echo measurements of dyssynchrony included:
￿ Interventricular mechanical delay (= APEI-PPEI)
￿ Atrio-ventricular delay (APEI)
￿ Time-delay to peak systolic velocity in the basal
segments of the septal and lateral wall using myocar-
dial velocity imaging (MVI) Q analysis.
A repeat transthoracic echo will be performed after
discharge from the cardiac intensive care unit (CITU)
between day 3 and 5 post surgery.
Baseline blood tests will be sent to measure:
￿ Full blood count (Haemoglobin, haematocrit and
mean cell volume)
￿ Creatinine (eGFR calculation)
￿ TnT: Troponin T
￿ BNP: Brain naturetic peptide
￿ NGAL: Neutrophil gelatinase associated lipocalin-
renal injury
Blood samples will be taken at baseline, 18 hours, 48
hours and 72 hours after admission to CITU.
An assessment of myocardial viability using dobuta-
mine stress echo (GE, Vivid 7, Horten, Norway) will be
considered for each patient. Each case will be discussed
with the cardiac surgeon before this test. Principal
exclusions will be a recent acute coronary syndrome or
episode of decompensated heart failure, valvular heart
disease, prior viability assessment or physician prefer-
ence. Viability assessment will be performed by an
experienced operator with ECG and blood pressure
monitoring. Dobutamine will be initially infused at a
rate of 5 microg/kg/min and increased in steps to 10,
20, 30 and 40 micrograms every 3 minutes. Atropine
0.25 mg will be added as a bolus at intervals of 1 minute
up to a total dose of 1 mg. The maximum target heart
rate = [(220-age) × 0.85]. Viability will be defined as 5
or more segments with abnormal resting function but
manifesting contractile reserve during dobutamine test-
ing [17].
Randomisation
Randomisation into 2 groups will be performed after
induction of anaesthesia using commercially available
Table 4 Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Age > 18 years Permanent pacemaker or
defibrillator
Sinus rhythm Infective endocarditis
Surgical revascularisation, valve surgery
or both
Hypertrophic cardiomyopathy
Off pump cardiac surgery
Permanent atrial arrhythmia
Renal failure (dialysis
dependent)
Emergency revascularisation.
Table 5 Echo protocol.
Echo window Modality Measurement
Parasternal long
axis
MMode LV internal dimensions
LV wall thickness
Septum to lateral wall delay
Colour
flow
Mitral regurgitation
Parasternal short
axis
PW
doppler
RVOT- pulmonary pre-ejection interval
(PPEI)
CW
doppler
PA acceleration time
Apical 4 chamber 2D LA and RA area
LVEDV and LVESV
MMode Long axis displacement- RV lateral/LV
septal and
lateral walls
Colour
flow
Mitral regurgitation
PW
doppler
Mitral inflow
LVOT- aortic pre-ejection interval (APEI)
IVRT
MVI Medial and lateral E’
Basal segments- peak velocity.
Apical 2 chamber 2D LVEDV and LVESV
MVI Basal segments- peak velocity.
Apical 3 chamber MVI Basal segments- peak velocity.
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Group 1 will be assigned to BiV pacing and group 2 to
standard pacing. Standard pacing will be atrial inhibited
pacing (AAI) unless right ventricular pacing is required,
then atrial-synchronous right ventricular pacing (DDD-
RV) is indicated. The intended duration of pacing will
be 48 hours, but could be modified by the attending
physician.
Operation
All patients will receive standard monitoring with ECG,
pulse oximetry, a radial arterial line with cardiac output
monitor attached to a Vigileo monitor (Flotrac MHD8R,
Edwards Lifesciences, Dominican Rep). Central line and
a pulmonary arterial catheter (either 7.5F CCO:
139HF75P or 7F TD: 131 F7, Edwards Lifesciences,
Irvine, USA) will be inserted after intravenous induction
of general anaesthesia. The techniques of anaesthesia
and cardio-pulmonary bypass (CPB) will be standar-
dized. After premedication with benzodiazepines, anaes-
thesia will be induced with iv propofol (1-2 mg/kg) and
fentanyl (10-20 μg/kg); muscle relaxation will be
achieved with rocuronium (1 mg/kg), vecuronium (0.2
mg/kg) or pancuronium bromide (0.1 - 0.2 mg/kg). The
airway will be intubated and mechanically ventilated
with oxygen, air and isoflurane 1-2%. Propofol and remi-
fentanil infusion may be used in addition to isoflurane
for maintenance of anaesthesia.
Intravenous fluids (Hartmann’ s solution or gelofusin),
vasopressors (metaraminol or phenylephrine) and ino-
tropes (enoximone or milirone, dopamine, noradrenaline
and adrenaline etc.) will be titrated according to
patients’ haemodynamic status. Prophylactic antibiotics
(cefuroxime and teicloplanin) and antifibrinolytic agents
such as tranexamic acid (2 g) will be administered prior
to sternotomy.
Operative monitoring will be identical in all patients.
The extracorporeal circuit will comprise a Stockert roller
pump (Shiley Inc, Irvine, CA), a Shiley S100 membrane
oxygenator, and polyvinylchloride tubes. Patients will be
given heparin just before the institution of CPB with 300
IU/kg, with additional dosing as necessary to maintain
the activated clotting time greater than 480 seconds.
Non-pulsatile extracorporeal circulation will be initiated
at flows of 2.4 to 2.6 L m
-2 min
-1. Moderate systemic
hypothermia (32°C nasopharyngeal) will be uniformly
used. Cardiac arrest will be achieved by infusion of 1 L of
cold blood cardioplegic solution and topical slush.
All distal anastomoses will be performed during a sin-
gle period of cross clamping, and the proximal anasto-
moses to the aorta will be completed during the re-
warming period. Extracorporeal circulation will be ter-
minated at a nasopharyngeal temperature of 37°C.
Heparin will be neutralized after the end of CPB with
protamine sulphate (1 mg/100 IU heparin).
Before weaning from the cardio-pulmonary bypass cir-
cuit, temporary unipolar epicardial pacing wires will be
sutured to the roof of the right atrium, the right ventri-
cular outflow tract and the postero-lateral free wall of
the left ventricle (first obtuse marginal territory) avoid-
ing scar tissue. There will be a total of 6 wires, 3 active
and 3 indifferent wires. The wires will be attached via
extension cables to a temporary external triple chamber
pacemaker (Osypka PACE 300, Germany).
Pacing will be commenced prior to separation from
the bypass circuit according to each patient’s randomisa-
tion. Subjects in the BiV group received DDD-BiV
pacing, base rate 90 bpm, AV interal 120 msec, max
tracking rate 110 bpm, VV interval -5 msec (-ve indicat-
ing LV pre-activation). The standard pacing group
received AAI pacing at base rate 90 bpm unless ventri-
cular pacing will be indicated. In this situation DDD-RV
pacing will be programmed, base rate 90 bpm, AV inter-
val 150 msec and max tracking rate 110 bpm. RV pacing
will be kept to a minimum.
Inotropes including, enoximone or milrinone in com-
bination with noradrenaline will be administered accord-
ing to haemodynamic requirements. The target range
for haemodynamic parameters after surgery:
￿ Mean arterial pressure 60-70 mm Hg
￿ Pulmonary capillary wedge pressure < 18 mm Hg
￿ Cardiac index 2.0-2.5 L/min/m
2
Haemodynamic studies
Haemodynamic studies will be performed after admis-
sion to the CITU after surgery (time = 0). The first
study will be performed using a pulmonary arterial (PA)
catheter, once the subject is euvolaemic and has a stable
inotropic requirement. Cardiac output/index, pulmonary
artery pressures, pulmonary capillary wedge pressure,
central venous pressure, mean arterial pressure (MAP)
and LV stroke work index will be recorded.
For thermodilution measurements, 3-5 sets of cardiac
output measurements will be obtained to ensure
Table 6 Variables considered at the time of
randomisation.
Parameter Reference
LV size ≤ 60 mm > 60 mm
QRS duration ≤ 120 msec > 120 msec
Euroscore ≤ 10 > 10
Intra-aortic balloon pump No Yes
Valve surgery No Yes
Ejection fraction ≤ 20% > 20%
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following pacing modes: atrial inhibited (AAI), right
ventricle only (VVI), dual chamber (DDD-RV) and
(DDD-LV) and BiV pacing. A minimum of 5 minutes
will be allowed between changing the pacing mode and
obtaining haemodynamic data. A pacing mode will be
discontinued if it causes > 10 mm Hg drop in MAP.
The base rate of pacing will be set at 10 beats above
intrinsic rhythm up to a maximum heart rate of 110
bpm. The pacing modes will be selected at random. The
studies will be repeated at 6 hours, 18 hours and 24
hours. After the 24 hour measurements the PA catheter
w i l lb er e m o v e d .C a r d i a co u t p u td a t aw i l lb ea l s o
obtained from the radial pulse contour analysis (FLO-
T R A C )m o n i t o ra tt h es a m et i m ep o i n t sa st h eP A
catheter, except for subjects with an intra-aortic balloon
pump.
Optimisation of the atrio-ventricular (AV) and inter-
ventricular (VV) delays will be performed at 18 hours. A
range of AV delays from 80-180 msec in 20 msec inter-
vals and then VV delays from -40 to 40 msec (-ve indi-
cating LV pre-activation) in 20 msec intervals will be
performed. The optimal AV and VV delays will be pro-
grammed for patients assigned to BiV pacing.
Endpoints
The primary endpoint of the trial is the duration of level
3 care [22] required after cardiac surgery. Level 3 care is
defined as the duration of invasive mechanical ventila-
tion or multiple organ support or multiple inotropes/
single inotrope and intra-aortic balloon pump. The
majority of patients would reach the primary endpoint
after extubation and then once weaned down to a single
inotrope. In the cases where inotropes are restarted, the
endpoint is taken to be the final transition from level 3
to level 2 care before discharge from the intensive care
unit.
Secondary endpoints are:
￿ Cardiac index at 18 hours (AAI v BiV).
￿ Duration and total dose of inotropes/intra aortic
balloon counter-pulsation.
￿ Renal function and requirement for
haemofiltration.
￿ Arrhythmia after surgery until hospital discharge.
￿ Change in brain naturetic peptide, troponin T and
neutrophil gelatinase associated lipocalin.
￿ Myocardial infarction, re-intubation or re-
sternotomy.
￿ 30 day all cause mortality.
Subjects will complete the trial 30 days after the
operation.
Statistical Analysis
No previous studies have investigated the effect of BiV
pacing on the duration of level 3 care after cardiac sur-
gery; previous studies have reported the total duration
of CITU stay.
Pokushalov et al [20] reported an average CITU stay
of 3.9 ± 0.6 days in the subjects after cardiac surgery,
compared with 2.5 ± 0.5 days in subjects who had BiV
pacing after cardiac surgery - a 36% reduction. We
anticipate that the duration of level 3 care will be
shorter than the duration of CITU stay, perhaps with
less variance, but we have used these mean values and
standard deviations for our power calculation.
Using the standard formula described by Campbell
and Matchin [23]:
Samplesize =
2 × (Z1α +Z 2β)
2 × σ2
δ2
s = standard deviation of the population
δ = anticipated benefit from the intervention
(Z1a +Z 2b) = normal distribution of function
(1-b) = 80% and a = 5%.
From standard tables (Z1a +Z 2b)
2 = 7.85
Samplesize =
2 × (7.85) × 0.62
(0.15 × 3.9)
2 =
5.652
0.342
= 16.5
In order to demonstrate a 15% reduction in the dura-
tion of level 3 care, with power 80% and with p < 0.05
for a two-sided test, the estimated total sample size
required is 34 subjects.
For haemodynamic comparison of paired data at 18
hours to compare BiV pacing to standard (AAI) pacing,
Hanke et al [24] observed a cardiac index of 2.7 ± 0.6
L/min/ml
2 in the standard pacing group. Allowing a 0.3
L/min/ml
2 (11%) improvement in cardiac index with
BiV pacing, significance 5% and power 80%, a sample
size of 32 subjects would be required.
Considering both of these previous studies, the mini-
mum number of subjects who will be recruited and rando-
mised into this study, will be 34; allowing for a 1/3 drop-
out rate, the minimum number to be recruited will be 45.
In the 2 cardiac surgical centres in which this study will be
performed the proportions of all patients undergoing car-
diac surgery who have impaired LV function and sinus
rhythm, and who would therefore be eligible for the study
are 2% and 8% (approximately 65 patients in a total of
1414 operations per year); this study should therefore be
feasible within a maximum of 2 years.
Data obtained for the primary endpoint and haemody-
namic studies will be analysed for normality using the
Kolmogorov-Smirnov test. Normally distributed vari-
ables will be analysed using unpaired or paired Student’s
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lysed using the Mann-Whitney U or Kruskal-Wallis test.
If continuous variables are not matched between inter-
vention and control groups at baseline, inter-group
comparisons will be made using an analysis of covar-
iance with adjustments made for baseline differences.
Changes in proportions for categorical data will be ana-
lysed with the Chi-square test or Fisher’s exact test.
Analysis will be intention-to-treat and a p-value of <
0.05 will be considered statistically significant.
Monitoring and safety
All adverse events, including serious adverse events
(SAE), will be recorded and followed up for the duration
of the study or until resolution. Assessment of adverse
events will be performed by study investigators. All
SAEs will be graded and reported to the sponsor. Any
suspected unexpected serious adverse reactions will be
reported to the sponsor and ethics committee.
Sub-study- control subjects
The beneficial effects of biventricular pacing are related
to the reversal of dyssynchrony. The prevalence of dys-
synchrony in patients with preserved LV function await-
ing cardiac surgery and the effect of bypass surgery on
indices of dyssynchrony requires further evaluation.
Therefore, patients in sinus rhythm, EF ≥ 45% and
awaiting revascularisation will be invited into the sub-
study. A transthoracic echocardiogram will be per-
formed (Table 5) before and after surgery, on day 3-5.
The data will be analysed for acute changes in mechani-
cal dyssynchrony after on-pump surgery.
Wang et al [25] measured the interventricular delay in
hypertensive subjects with preserved LV function- 21
msec ± 19. Using a 5% significance level and 80%
p o w e r ,t od e t e c ta2 0m s e cc h a n g ei nI V M D ,as a m p l e
size of 8 subjects is needed.
Summary
This trial is designed to assess the clinical and haemody-
namic response to temporary BiV pacing after cardiac
surgery. All subjects in sinus rhythm with severe LV sys-
tolic impairment (EF ≤ 35%) will be enrolled, irrespec-
tive of QRS duration or pre-operative requirement for
intra aortic balloon counter pulsation.
A reduction in the length of level 3 care, acute hae-
modynamic optimisation or protection against arrhyth-
mias or renal dysfunction/haemofiltration with BiV
pacing would be a clinically significant finding.
Trial status
The trial started recruitment in February 2009 and we
have recruited 31 patients.
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output; CI: Cardiac index; CITU: Cardiac intensive care unit; CRT: Cardiac
resynchronisation therapy; CW: Continuous wave Doppler; DCM: Dilated
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Acknowledgements
SJR has received an unrestricted educational grant from St Jude Medical.
ZRY is a NISCHR fellow.
Author details
1Wales Heart Research Institute, Heath Park, Cardiff. CF14 4XN. UK.
2University
Hospital of Wales, Heath Park, Cardiff. CF14 4XW. UK.
3Morriston Hospital,
Swansea. SA6 6NL. UK.
Authors’ contributions
All authors have been involved in the design of the study and the drafting
of the manuscript and will participate in patient recruitment and. SJR will
collect the data including haemodynamic measurements using the
pulmonary arterial catheter and the trial transthoracic echocardiograms. AGF
will perform the dobutamine viability studies. All authors will be involved in
the statistical analysis and data interpretation. All authors have read and
approved the final manuscript.
Authors’ information
SJR is a Cardiology Research Fellow.
Competing interests
The sponsor form this trial is the Cardiff and Vale Local Heath Board
(formerly the University of Wales NHS Trust) Cardiff, Wales, UK.
Received: 22 July 2011 Accepted: 20 February 2012
Published: 20 February 2012
References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-
Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A,
Mebazaa A, Nieminen M, Priori SG, Swedberg K: Esc guidelines for the
diagnosis and treatment of acute and chronic heart failure 2008: The
task force for the diagnosis and treatment of acute and chronic heart
failure 2008 of the european society of cardiology. Developed in
collaboration with the heart failure association of the esc (hfa) and
endorsed by the european society of intensive care medicine (esicm).
Eur J Heart Fail 2008, 10(10):933-989.
2. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF,
Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO: Navigating the
crossroads of coronary artery disease and heart failure. Circulation 2006,
114(11):1202-1213.
3. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ: The
national heart failure audit for england and wales 2008-2009. Heart 2011,
97(11):876-886.
4. Gissi-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and
together on 6-week mortality and ventricular function after acute
myocardial infarction. Gruppo italiano per lo studio della sopravvivenza
nell’infarto miocardico. Lancet 1994, 343(8906):1115-1122.
5. Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. The acute
infarction ramipril efficacy (aire) study investigators. Lancet 1993,
342(8875):821-828.
Russell et al. Trials 2012, 13:20
http://www.trialsjournal.com/content/13/1/20
Page 7 of 86. The cardiac insufficiency bisoprolol study ii (cibis-ii): A randomised trial.
Lancet 1999, 353(9146):9-13.
7. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in
patients with left-ventricular dysfunction: The capricorn randomised trial.
Lancet 2001, 357(9266):1385-1390.
8. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol cr/xl
randomised intervention trial in congestive heart failure (merit-hf).
Lancet 1999, 353(9169):2001-2007.
9. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van
Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J: Eplerenone
reduces mortality 30 days after randomization following acute
myocardial infarction in patients with left ventricular systolic dysfunction
and heart failure. J Am Coll Cardiol 2005, 46(3):425-431.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J,
Wittes J: The effect of spironolactone on morbidity and mortality in
patients with severe heart failure. Randomized aldactone evaluation
study investigators. N Engl J Med 1999, 341(10):709-717.
11. Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S,
Foster E, Huang DT, Klein HU, Zareba W, Eldar M, Goldenberg I: Reverse
remodeling and the risk of ventricular tachyarrhythmias in the madit-crt
(multicenter automatic defibrillator implantation trial-cardiac
resynchronization therapy). Journal of the American College of Cardiology
2011, 57(24):2416-2423.
12. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, Hall WJ,
Pfeffer MA, Moss AJ: Effect of cardiac resynchronization therapy on
reverse remodeling and relation to outcome: Multicenter automatic
defibrillator implantation trial: Cardiac resynchronization therapy.
Circulation 2010, 122(10):985-992.
13. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K,
James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M,
Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P,
Serruys PW, Silber S, Sousa Uva M, Taggart D, Vahanian A, Auricchio A,
Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R,
Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA,
Tendera M, Vardas PE, Widimsky P, Alfieri O, Dunning J, Elia S, Kappetein P,
Lockowandt U, Sarris G, Vouhe P, von Segesser L, Agewall S, Aladashvili A,
Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A,
Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K,
Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K,
Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R,
Thielmann M, Wheatley DJ, Windecker S, Zembala M: Guidelines on
myocardial revascularization: The task force on myocardial
revascularization of the european society of cardiology (esc) and the
european association for cardio-thoracic surgery (eacts). European heart
journal 2010, 31(20):2501-2555.
14. Coronary artery surgery study (cass): A randomized trial of coronary
artery bypass surgery. Survival data. Circulation 1983, 68(5):939-950.
15. Eleven-year survival in the veterans administration randomized trial of
coronary bypass surgery for stable angina. The veterans administration
coronary artery bypass surgery cooperative study group. The New
England journal of medicine 1984, 311(21):1333-1339.
16. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS,
Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H,
Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO,
Rankin GR, Jones RH, Rouleau JL: Coronary-artery bypass surgery in
patients with left ventricular dysfunction. The New England journal of
medicine 2011, 364(17):1607-1616.
17. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P,
Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS,
Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L,
Velazquez EJ, Jones RH, Panza JA: Myocardial viability and survival in
ischemic left ventricular dysfunction. The New England journal of medicine
2011, 364(17):1617-1625.
18. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE: Myocardial viability
testing and impact of revascularization on prognosis in patients with
coronary artery disease and left ventricular dysfunction: A meta-analysis.
J Am Coll Cardiol 2002, 39(7):1151-1158.
19. Pigott DW, Nagle C, Allman K, Westaby S, Evans RD: Effect of omitting
regular ace inhibitor medication before cardiac surgery on
haemodynamic variables and vasoactive drug requirements. British
journal of anaesthesia 1999, 83(5):715-720.
20. Pokushalov E, Romanov A, Prohorova D, Cherniavsky A, Goscinska-Bis K,
Bis J, Bochenek A, Karaskov A: Coronary artery bypass grafting with
concomitant cardiac resynchronisation therapy in patients with
ischaemic heart failure and left ventricular dyssynchrony. European
journal of cardio-thoracic surgery: official journal of the European Association
for Cardio-thoracic Surgery 2010, 38(6):773-780.
21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi L: The effect of cardiac resynchronization on morbidity and
mortality in heart failure. N Engl J Med 2005, 352(15):1539-1549.
22. Levels of critical care for adult patients. London: The Intensive Care
Society; 2002.
23. Campbell M, Matchin D: Medical statistics: A common sense approach.
John Willey and sons Ltd;, 2 1999.
24. Hanke T, Misfeld M, Heringlake M, Schreuder JJ, Wiegand UK, Eberhardt F:
The effect of biventricular pacing on cardiac function after weaning
from cardiopulmonary bypass in patients with reduced left ventricular
function: A pressure-volume loop analysis. The Journal of thoracic and
cardiovascular surgery 2009, 138(1):148-156.
25. Wang YC, Hwang JJ, Lai LP, Tsai CT, Lin LC, Katra R, Lin JL: Coexistence and
exercise exacerbation of intraleft ventricular contractile dyssynchrony in
hypertensive patients with diastolic heart failure. American Heart Journal
2007, 154(2):278-284.
26. Breithardt OA, Stellbrink C, Kramer AP, Sinha AM, Franke A, Salo R,
Schiffgens B, Huvelle E, Auricchio A: Echocardiographic quantification of
left ventricular asynchrony predicts an acute hemodynamic benefit of
cardiac resynchronization therapy. J Am Coll Cardiol 2002, 40(3):536-545.
27. Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D, Pavin D,
Lazarus A, Daubert JC: Acute hemodynamic effects of biventricular ddd
pacing in patients with end-stage heart failure. J Am Coll Cardiol 1998,
32(7):1825-1831.
28. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H,
Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J: Effect of pacing
chamber and atrioventricular delay on acute systolic function of paced
patients with congestive heart failure. The pacing therapies for
congestive heart failure study group. The guidant congestive heart
failure research group. Circulation 1999, 99(23):2993-3001.
29. Kass DA, Chen CH, Curry C, Talbot M, Berger R, Fetics B, Nevo E: Improved
left ventricular mechanics from acute vdd pacing in patients with
dilated cardiomyopathy and ventricular conduction delay. Circulation
1999, 99(12):1567-1573.
30. Eberhardt F, Heringlake M, Massalme MS, Dyllus A, Misfeld M, Sievers HH,
Wiegand UK, Hanke T: The effect of biventricular pacing after coronary
artery bypass grafting: A prospective randomized trial of different
pacing modes in patients with reduced left ventricular function. The
Journal of thoracic and cardiovascular surgery 2009, 137(6):1461-1467.
31. Evonich RF, Stephens JC, Merhi W, Dukkipati S, Tepe N, Shannon F,
Altshuler J, Sakwa M, Bassett J, Hanson E, Boura J, O’Neill WW, Haines DE:
The role of temporary biventricular pacing in the cardiac surgical
patient with severely reduced left ventricular systolic function. The
Journal of thoracic and cardiovascular surgery 2008, 136(4):915-921.
32. Hamad MA, van Gelder BM, Bracke FA, van Zundert AA, van Straten AH:
Acute hemodynamic effects of cardiac resynchronization therapy in
patients with poor left ventricular function during cardiac surgery.
Journal of Cardiac Surgery 2009, 24(5):585-590.
33. Muehlschlegel JD, Peng YG, Lobato EB, Hess PJ Jr, Martin TD, Klodell CT Jr:
Temporary biventricular pacing postcardiopulmonary bypass in patients
with reduced ejection fraction. Journal of Cardiac Surgery 2008,
23(4):324-330.
34. Dzemali O, Bakhtiary F, Israel CW, Ackermann H, Moritz A, Kleine P: Impact
of different pacing modes on left ventricular function following
cardiopulmonary bypass. Thorac Cardiovasc Surg 2008, 56(2):87-92.
doi:10.1186/1745-6215-13-20
Cite this article as: Russell et al.: Temporary epicardial cardiac
resynchronisation versus conventional right ventricular pacing after
cardiac surgery: study protocol for a randomised control trial. Trials 2012
13:20.
Russell et al. Trials 2012, 13:20
http://www.trialsjournal.com/content/13/1/20
Page 8 of 8